Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD Patients

Pulmonary Disease, Chronic Obstructive Clinical Trial

Official title:

Randomised, Double-Blind, Placebo-Controlled, 4-Way Cross-Over Study to Assess the Efficacy and Safety of a Single Dose of Orally Inhaled BEA 2180 BR (Doses 80, 200 and 800 μg) in COPD Patients Followed by an Open-Label, Active-Control (Tiotropium 72 μg)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02242279
• Other study ID #: 1205.3
• Status: Completed
• Phase: Phase 2
• First received: September 16, 2014
• Last updated: September 16, 2014
• Start date: June 2004

Study information

• Verified date: September 2014
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Federal Agency for Medicinal Products and Health ProductsNetherlands: Medicines Evaluation Board (MEB)
• Study type: Interventional

Clinical Trial Summary

Study to investigate the dose-dependent bronchodilator effect and the safety of single inhalation doses of BEA 2180 inhaled via Respimat® compared to placebo in patients with stable Chronic Obstructive Pulmonary Disease (COPD)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 37
• Est. primary completion date: December 2004
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

1. All patients have to sign and date an informed consent consistent with International committee on harmonisation (ICH) - Good Clinical Practice (GCP) guidelines prior to participation in the trial, which included medication washout and restrictions

2. All patients must have a diagnosis of chronic obstructive pulmonary disease and must meet the following spirometric criteria:

Patients must have relatively stable, moderate to severe airway obstruction with an FEV1 = 60% of predicted normal and FEV1 = 70% of FVC (Visits 1 and 2)

3. All patients must have an increase in FEV1 of at least 12% from baseline 45 min after inhalation of 80 µg of ipratropium inhaled via Hydro Fluoro Alkane (HFA) - Metered Dose Inhaler (MDI)

4. Male or female patients 40 years of age or older. Female patients of child bearing potential could not participate in this study

5. Patients must be current or ex-smokers with a smoking history of more than 10 pack/years

• (Patients who have never smoked cigarettes must be excluded)

6. Patients must be able to perform technically acceptable pulmonary function tests and inhale medication in a competent manner from the Respimat® device and the HandiHaler®

Exclusion Criteria:

1. Patients with significant diseases other than Chronic Obstructive Pulmonary Disease (COPD) must be excluded. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study

2. Patients with clinically relevant abnormal baseline hematology, blood chemistry, or urinalysis, if the abnormality defines a significant disease

3. Patients with significant prostatic hyperplasia

4. Patients with a recent history (i.e. one year or less) of myocardial infarction

5. Patients with any unstable or life-threatening cardiac arrhythmia or patients who have been hospitalized for such an event within the past year

6. Patients with a history (less than 3 years) of cardiac failure, cor pulmonale or cardiac arrhythmia requiring drug therapy

7. Patients with a malignancy for which the patient has undergone resection, radiation therapy or chemotherapy within the last five years. Patients with treated basal cell carcinoma are allowed

8. Patients with known narrow-angle glaucoma

9. Patients with a history of asthma, allergic rhinitis or who have a total blood eosinophil count = 600/mm3. A repeat eosinophil count was not conducted in these patients

10. Patients with a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or clinically evident bronchiectasis

11. Patients with known active tuberculosis

12. Patients with a history of and/or active significant alcohol or drug abuse

13. Patients who have undergone thoracotomy with pulmonary resection. Patients with a history of thoracotomy for other reasons must be excluded

14. Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the Screening Visit (Visit 1)

15. Patients who regularly used daytime oxygen therapy

16. Patients who have taken an investigational drug within one month or six half lives (whichever is greater) prior to Screening Visit (Visit 1)

17. Patients who are being treated with oral beta-adrenergic

18. Patients who are being treated with beta-blockers

19. Patients who are being treated with cromolyn sodium or nedocromil sodium

20. Patients who are being treated with antihistamines (H1 receptor antagonists), antileukotrienes or leukotriene receptor antagonists for asthma or excluded allergic conditions

21. Patients using oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day

22. Patients with known hypersensitivity to anticholinergic drugs, beta-adrenergic, lactose or any other components of the medication delivery systems

23. Pregnant or nursing women or women of childbearing potential. Female patients have to be either:

• Surgically sterilized by hysterectomy or bilateral tubal ligation or

• Post-menopausal for at least two years

24. Patients with previous participation (receipt of randomized treatment) in this study

25. Patients who are participating in another study

26. The randomization of patients with any respiratory infection or COPD exacerbation in the six weeks prior to the Screening Visit (Visit 1) or during the baseline period must be postponed. Patients could be randomized six weeks following recovery from the infection or exacerbation

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Disease
• Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• BEA 2180 BR

• Tiotropium

• Placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Mean Forced Expiratory Volume in 1st second (FEV1)		23 and 24 hours after single inhalation	No
Secondary	Change in FEV1 Area under the concentration-time curve over the respective time interval (AUCtime-interval)		predose, 30, 60 minutes, 2, 3, 4, 6, 8, 10, 12, 23, 24, 26 and 28 hours after inhalation of each single dose	No
Secondary	Peak FEV1		within 3 hours after inhalation of each single dose	No
Secondary	Time to peak bronchodilatory response		within 3 hours after inhalation of each single dose	No
Secondary	Change in Forced Vital Capacity (FVC) AUCtime-interval		predose, 30, 60 minutes, 2, 3, 4, 6, 8, 10, 12, 23, 24, 26 and 28 hours after inhalation of each single dose	No
Secondary	Change in individual FEV1 measurements		up to 71 days	No
Secondary	Change in individual FVC measurements		up to 71 days	No
Secondary	Number of patients with adverse events		up to 85 days	No
Secondary	Area under the plasma concentration-time curve over the respective time interval (AUCtime-interval)		predose, 5 min, 30min, 2 h, 8 h , 24 h	No
Secondary	Pre-dose plasma concentration immediately before the inhalation of each single dose (Cpre)		predose	No
Secondary	Maximum measured plasma concentration following the inhalation of each single dose (Cmax)		predose, 5 min, 30min, 2 h, 8 h , 24 h	No
Secondary	Time from dosing to the maximum plasma concentration the inhalation of each single dose of randomised treatment (tmax)		predose, 5 min, 30min, 2 h, 8 h , 24 h	No
Secondary	Amount of unchanged drug excreted over the respective time intervals (Aetime-interval)		predose, 0-4 h, 4-24 h	No
Secondary	Renal clearance of the analyte from the time point t1 until the time point t2 (CLR,t1-t2)		predose, 0-4 h, 4-24 h	No
Secondary	Fraction of analyte eliminated in urine from different time intervals (fetime-interval)		predose, 0-4 h, 4-24 h	No
Secondary	Peak FVC		within 3 hours after inhalation of each single dose	No

External Links

•   Link